-
2025-521441-24-00
7
2026-01-19
Advanced or Metastatic Solid Tumors
-
2024-519494-19-00
5
2025-12-22
Nutritional and metabolic diseases
-
2024-517614-14-00
4
2025-11-28
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
-
2023-508612-29-00
5
2025-11-07
Advanced Melanoma
-
2024-519654-37-00
10
2025-11-07
Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma.
-
2024-517866-40-00
4
2025-09-29
Moderate-to-severe Asthma
-
2024-516020-33-00
4
2025-06-26
Grave’s Disease
-
2024-512696-12-00
4
2025-06-24
BCR-ABL1+ Chronic Myeloid Leukemia
-
2024-517423-40-00
5
2025-06-23
Metastatic Castration-Resistant Prostate Cancer
-
2024-515411-21-00
4
2025-06-18
Rett Syndrome (RTT)
-
2024-515764-31-00
10
2025-06-13
Non-small cell lung cancer
-
2023-508773-82-00
5
2025-05-06
Stage IIB-IIIB (N2) resectable non small cell lung cancer
-
2024-517284-23-00
5
2025-04-23
Active Psoriatic Arthritis
-
2023-506206-38-00
4
2025-04-09
Diffuse Large B-cells non-Hodgkin Lymphoma
-
2023-504904-26-00
5
2025-04-07
Progressive Pulmonary Fibrosis
-
2024-513550-30-00
5
2025-03-28
Newly diagnosed Glioblastoma
-
2024-515445-42-00
5
2025-03-24
Node-positive, Estrogen Receptor-positive, HER2-negative, Early Breast
-
2023-509070-36-00
5
2025-03-18
Major Depressive Disorder with Insomnia Symptoms
-
2024-514333-37-00
4
2025-02-25
Advanced Metastatic Ocular/Uveal Melanoma
-
2022-502877-41-01
9
2025-02-10
Pulmonary sarcoidosis with or without extrapulmonary manifestations
-
2023-504022-19-01
5
2024-12-13
Polymyositis or dermatomyositis according to 2017 EULAR / ACR classifi
-
2022-500455-23-00
5
2024-12-11
Candidemia
-
2024-518891-29-00
4
2024-11-18
MM and NSCLC patients resistant to anti-PD-1/PD-L1 therapy
-
2023-508517-16-00
7
2024-11-10
Advanced Solid Tumors with a KRAS p.G12C Mutation